Lp-PLA2 Activity Testing: The Clinical and Laboratory Perspective [A Test in Focus Webinar]

TUESDAY, NOVEMBER 24, 2015  |  2 – 3 pm CST

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker of atherosclerosis and is often referred to by the trademark name “The PLAC Test.” Lp-PLA2 is an enzyme produced mainly by monocytes and macrophages that converts phosphotidylcholine into 2 proinflammatory and proatherogenic molecules: nonesterified fatty acids (NEFA) and lysophosphatidylcholine (LPC). It is also found in the circulation bound to low-density lipoprotein and several studies have shown that patients with high levels of Lp-PLAin the blood are at higher risk of a cardiovascular event such as myocardial infarction or stroke.

This one-hour webinar will examine Lp-PLA2 and the benefits of ordering the Lipoprotein-Associated Phospholipase A2 Activity Test (Mayo ID: PLACA) offered by Mayo Medical Laboratories.


Brent Westra

Brent Westra is a Marketing Segment Manager at Mayo Medical Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.